



For release: 14 September 2009

## Xention Announces Attendance at Three Upcoming Conferences

**CAMBRIDGE, UK** - XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs is pleased to announce that it will be presenting at three investor and partnering conferences over the coming weeks.

Xention will present an update of its clinical and pre-clinical programmes in atrial fibrillation, overactive bladder and autoimmune disease to audiences at the Sachs Biotech in Europe Investor Forum, Biopartnering Europe and BioEurope. The company's lead atrial fibrillation programme targeting Kv1.5 is currently in clinical development and its IKACH programme, also for atrial fibrillation, is at the pre-clinical stage; its overactive bladder programme targets the TRPV1 channel and is in clinical development; and its autoimmune programme targeting the channel Kv1.3 is at the pre-clinical stage.

- The **Sachs Biotech in Europe Investor Forum** being held in Zurich on 14 and 15 September will include an audience of over 300 investors, analysts & media. The conference is recognised as an international stage for those interested in investing in the biotech and life science industry, and, as a presenting company, Xention will have access some of the leading analysts and investors from Europe and beyond.
- The **Bio-Partnering Europe** conference will be held in London from 11 to 14 October. Now in its 17th year, this well established forum offers excellent partnering opportunities in the life science industry. Over the four days of networking, Xention will meet with decision-makers from leading biotechnology, pharmaceutical, and investment companies from around the world.

- The **BIO-Europe 2009** event held in Vienna from 2 to 4 November is one of the world's largest dedicated biotechnology partnering conference. Over 2,500 global decision-makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships.

'We are delighted to have secured presenting slots at these three prestigious conferences', commented Tim Brears, CEO of Xention. 'Through these we will receive great exposure and be able to present our proprietary technology and clinical development programmes. We look forward to discussing our approach with investors and potential partners alike.'

For further information, please contact:

Tim Brears  
CEO  
Xention Limited

+44 (0)1223 493900

Anna Dunphy  
De Facto Communications

+44 (0)20 7861 3838

**Notes to Editors:**

Should you wish to meet the management of Xention on a one-to one basis at any of the above conferences, please feel free to contact the company directly or through us on [m.wort@defacto.com](mailto:m.wort@defacto.com) or [a.dunphy@defacto.com](mailto:a.dunphy@defacto.com)

Xention Ltd is a leader in the discovery and development of ion channel-modulating drugs. The Company's potential breakthrough drugs in clinical development include XEN-D0101, a new atrial selective potassium channel blocker for atrial fibrillation, and XEN-D0501, a novel ion channel modulator for the treatment of overactive bladder. Xention also has preclinical research programmes in atrial fibrillation, pain and autoimmune disease. The Company uses proprietary ion channel expertise and technologies to accelerate the discovery of potent and selective ion channel drugs. In particular, Xention is a leader in the use of true electrophysiological data, ion channel chemoinformatics and experienced medicinal chemistry to identify potent new small molecule drugs in this rapidly evolving field of medicine. For further information, please see their website <http://www.xention.com>.